Cellectis S.A.

Stage 4 · Declining · week 6

As of Oct 22, 2026, Cellectis is in Stage 4, the downtrend phase, now in week 6 (since Sep 17, 2026). It closed at $0.98, 81.8% below its 52-week high and below its 200-day average, which is falling.

$0.98

+0.67% today

$98.2M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is CLLS early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 30w

S2 28w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S1 2w → S4 11w → S1 2w → S2 13w → S3 11w → S2 5w → S3 3w → S4 9w → S1 5w → S4 30w → S1 11w → S2 28w → S3 11w → S2 1w → S1 5w → S4 11w → S1 2w → S4 5w current

Total tracked: 165 weeks across 18 stage runs.

CLLS among Biotechnology439th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…439	CLLSCellectis S.A.	Stage 4 · wk 6	14	−32.3%

vs 52W High

-81.8%

$0.93 lo$5.35 hi

81.8% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 6

1w13w26w

Week 6, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-69.2%

200 DMA: $3.17 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

1.07x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-32.3%

-65.7%

-75.1%

YTD

-79.7%

-73.5%

Scan Membership

Breakout Watch

Latest: 2024-05-16

6 appearances in last 60 days. First seen: 2020-01-09.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 6 · Vol 1.07x

2026-10-21S4

Wk 5 · Vol 2.42x

2026-10-20S4

Wk 5 · Vol 2.54x

2026-10-19S4

Wk 5 · Vol 2.10x

2026-10-16S4

Wk 5 · Vol 0.76x

2026-10-15S4

Wk 5 · Vol 0.97x

2026-10-14S4

Wk 4 · Vol 0.96x

2026-10-13S4

Wk 4 · Vol 0.53x

2026-10-12S4

Wk 4 · Vol 1.23x

2026-10-09S4

Wk 4 · Vol 0.77x

2026-10-08S4

Wk 4 · Vol 1.11x

2026-10-07S4

Wk 3 · Vol 0.65x

Moving averages & range

50 DMA

$2.14

200 DMA

$3.17

52W High

$5.35

52W Low

$0.93

5D Low

$0.93

Resistance levels (recent highs)

20d High

$1.51

60d High

$3.56

120d High

$4.07

250d High

$5.35

Next resistance

+54.9%

to 20d High

ROE

-94.5%

Profit margin -102.3%

Dividend Yield

0.00%

P/B 1.7

Cellectis: quick answers

What stage is Cellectis in?

As of Oct 22, 2026, Cellectis (CLLS) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 17, 2026 and is in week 6. What the four stages mean

Is Cellectis in an uptrend?

No. Cellectis is in a Stage 4 downtrend. It trades 69.2% below its 200-day average, which is falling.

How far is Cellectis from its 52-week high?

Cellectis closed at $0.98 on Oct 22, 2026, 81.8% below its 52-week high of $5.35. Its 52-week low is $0.93.

How has Cellectis performed over the past year?

As of Oct 22, 2026, Cellectis is down 73.5% over the past year and down 79.7% so far in 2026.

Which sector and industry is Cellectis in?

Cellectis is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). In addition, the company Melanoma, for treatment of unresectable or metastatic melanoma. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.